2022-Bangkok-CareAcross

THANOS KOSMIDIS: Good morning from me as well. I'm grateful to MIT and, of course, [INAUDIBLE] for hosting us this morning, but, of course, all of you for being here with us today because it's all about you. And I will apologize in advance for putting the word you and cancer in the same sentence, but it's realistic, right?

Cancer has many different sides. And there's a good side-- things are improving. It's becoming a chronic condition. Patients live longer. They stay out of the hospital. They don't have to go to the hospital all this time. At the same time, these treatments are still toxic. They affect people. You've seen that. You have the visuals in your minds. Nobody's prepared for these treatments. The caregivers, the care homes are not prepared. But also the health care system-- it's costly and it affects-- the resources are not there. So people live longer, but do they necessarily live better? Probably not always.

So I'm going to spend a few more minutes to walk you through what we have been doing over the past several years in several countries and several cancer types to help patients improve their quality of life in parallel with their medical treatment. And it is just going to be a schematic, a very high-level diagram, but I can demo this outside.

So patients interact with an online platform. Their data is being ingested and it's analyzed with advanced algorithms. Several thousands of combinations emerge from these algorithms. It's a complicated condition. Life is complicated. But then, our research database of thousands of applications, which is being crossed ongoing, it actually delivers impactful information to these individuals so they can improve the quality of life. I'll get you through the impact in a bit.

But this is not the whole story because, in parallel, we're not forgetting about the doctors, the clinics, the industry, real-world data, remote patient monitoring, is a reality through these capabilities. Again, we can talk about that more outside.

Let's zoom out a bit. These are some of the modules that we have in place to help patients improve quality of life. Side effects-- again, we all have seen the pictures. We all know some things about this. But then, also, of course, nutrition, exercise emotional support, comorbidities-- all of us have different conditions that we struggle with. So this is important.

So we're going to be focusing a bit more on side effects in the next few slides, and I'm going to be sharing with you some of the evidence we've shared with the scientific congresses. I'm not going to go into very deep, but again, we can discuss further.

Especially with side effects, this is one of the key posters we had at ASCO, the key oncology congress globally. And the percentages you see here reflect the improvement in the side effect frequency. Imagine being able to say that without drugs, without a medical intervention, but in parallel with the evidence-based interventions, you can reduce 30%, 40%, 50%, 60% of side effect impact on cancer patients-- this across several thousand patients in several countries.

Again, now we can go a bit deeper into this analysis and visit the power of data because you can see the comparative effectiveness across the people who have metastatic disease, who have other conditions. This is where the personalization really gets into gear. You can tailor the right treatment to the right individual based on what would work best for them.

Please, there's not going to be an exam later on. You don't need to read through the text. I can send you the deck later on if you like. But do you know what the most common side effect for patients in cancer? It's actually fatigue. It's not the fatigue I'm having now because of jet lag and low sleep. It's a fatigue which will not really help somebody if they've sleep for hours and hours. It's debilitating.

This year, earlier this year in Chicago, where we compare and contrast to different interventions, different self-care interventions for patients to help improve fatigue. And so this leads to more and more evidence generation about improving quality of life and improving the healthcare professionals' workflows as well.

Just keep going with different kind of interventions-- these are analyses for available data in breast cancer, different treatments, different side effects, different supplements that patients are getting to help them reduce those side effects-- a lot of interesting insights there.

Switching gears for a little bit on lung cancer, another very common condition-- two combination therapies which are considered equivalent by the medical community, quite rightly so in terms of medical outcomes, their side effect profiles are very different. So this is insight that professionals can actually take into consideration when they're prescribing equivalent treatments to their patients.

So we could go on and on. This is not the goal. The goal is to actually make things happen, not for the past, but from now on. So this is what we're here for.

On the right-hand side of this slide, you can see some of the capabilities I went through. We're talking about digital therapeutics. It's a hyped term, so bear with us. It is about helping patients improve quality of life, remote patient monitoring, improving the patient engagement, collecting data, and ongoing coaching-- long-term improvements. These are some of the things we can do when we have evidence to generate and we keep generating.

But I'm not sure I can really capture, on the left-hand side, what could be the benefit, or what categories of benefits we can have. But essentially, what we're here for is for you to consider if cancer is in your interest, if cancer patients are in your focus, if you feel that having evidence-based, data-driven, personalized, and impactful digital therapeutic solutions for patients and the caregivers and the healthcare system, then let's talk. Let's find out how we can make a difference. Let's find out how we could expand in Southeast Asia, how we can make this happen in a very personalized way based on the local needs, the local realities, the local languages that can actually make a difference on cancer patients' lives.

Thank you very much for your attention. I'll look forward to your questions now and later and outside. Thank you again.